explore -WSS

explore

author：entertainment 2025-10-01 21:47:42 - browse：3

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Biotech incubator Curie.Bio graduates its first startup

WSS

The Sacklers, horror, and ‘The Fall of the House of Usher’

FDA drug safety: Singulair case shows systemic surveillance flaws

Biden administration opens offers in Medicare drug price negotiations

UCSF medical school apologizes for unethical prisoner experiments

Covid misinformation case heads to Supreme Court

MoonLake credibility takes another hit with mid

knowledge

explore

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Do digital therapeutics have a future in medicine?

Anesthesiologist group: stop taking Ozempic before surgery

Time to name cancers by genetics, not organ of origin, expert says

Hepatitis C has a cure — but many Americans still lack access to it

Congressmen charge Covid hearing ‘could have been an email’

Jerome Adams on the need for new antivirals for Covid

The new shift in health care is toward less care

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The Sacklers, horror, and ‘The Fall of the House of Usher’

leisure time

SAMSHA loosens regulations on methadone treatment centers

Novo Nordisk to expand supply of Wegovy for U.S. patients

Quicker fix for pulse oximeters urged during FDA public meeting

What we need to know about Arena Bioworks

White House calls on federal agencies to crack down on AI abuses

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Wikipedia

focus

explore

leisure time